TherapeuticsMD, Inc. (NASDAQ:TXMD) Short Interest Update

TherapeuticsMD, Inc. (NASDAQ:TXMD) was the target of a significant growth in short interest in October. As of October 31st, there was short interest totalling 29,700 shares, a growth of 26.4% from the October 15th total of 23,500 shares. Based on an average daily trading volume, of 13,700 shares, the days-to-cover ratio is presently 2.2 days. Approximately 0.3% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on TherapeuticsMD in a report on Friday. They issued a “hold” rating for the company.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP lifted its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the period. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Stock Down 4.1 %

TXMD stock opened at $1.40 on Friday. TherapeuticsMD has a 52 week low of $1.36 and a 52 week high of $3.07. The business has a 50-day simple moving average of $1.61 and a 200 day simple moving average of $1.78.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.